|Articles|December 15, 2002
- BioPharm International-12-15-2002
- Volume 15
- Issue 1
Guest Editorial: EPO Saga to Augur Regulatory Change?
Author(s)Gordon Kelley
by Gordon Kelley, BioPharm International magazine
Advertisement
Articles in this issue
about 23 years ago
BioPharm International Five-Year Article Indexabout 23 years ago
Evaluation of Extractables from Product-Contact Surfacesabout 23 years ago
Monitoring and Controlling Biocatalytic ProcessesNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
3
Industry Outlook 2026: Key Forces Transforming Drug Pipelines (Part 2)
4
Eli Lilly Announces New $3.5 Billion Manufacturing Facility in Pennsylvania
5
